# OnCo record abl1 (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/abl1/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "abl1" ;
  schema:name "ABL1"@en ;
  schema:alternateName "c-ABL"@en, "ABL"@en, "JTK7"@en, "ABL proto-oncogene 1, non-receptor tyrosine kinase"@en, "ABL1" ;
  schema:description "ABL1 is the kinase half of the BCR::ABL1 fusion that causes chronic myeloid leukaemia. The CML drugs bind the ABL1 kinase domain, most in its ATP pocket and asciminib in a separate pocket that locks it shut."@en ;
  schema:url <https://onco.cc/targets/abl1/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76>, <https://www.uniprot.org/uniprotkb/P00519/entry>, <https://www.ncbi.nlm.nih.gov/gene/25> ;
  onco:tag "wave5-target" ;
  onco:targetClass "kinase" ;
  schema:sameAs <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000097007>, <https://www.uniprot.org/uniprotkb/P00519/entry>, <https://www.ncbi.nlm.nih.gov/gene/25> ;
  onco:related <https://onco.cc/targets/bcr-abl/> ;
  onco:cancers <https://onco.cc/cancers/cml-chronic-phase/>, <https://onco.cc/cancers/cml-advanced-phase/>, <https://onco.cc/cancers/all-leukemia/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/asciminib/>, <https://onco.cc/drugs/dasatinib/>, <https://onco.cc/drugs/ponatinib/> ;
  onco:pathways <https://onco.cc/pathways/bcr-abl1-signalling/>, <https://onco.cc/pathways/cml-signalling/> .